Fortress Biotech Amends Credit Agreement with Oaktree

Fortress Biotech ( (FBIO) ) has shared an announcement.

On December 12, 2025, Fortress Biotech, Inc. amended its Credit Agreement with Oaktree Fund Administration, extending the loan maturity date to June 30, 2028, and adjusting the principal repayment schedule. The amendment also revised the financial covenant for Journey Medical Corporation’s net sales requirements, with specific targets set for each fiscal quarter through 2026. Additionally, Fortress Biotech granted warrants to lenders for purchasing shares of its common stock, with provisions for anti-dilution adjustments.

The most recent analyst rating on (FBIO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.

Spark’s Take on FBIO Stock

According to Spark, TipRanks’ AI Analyst, FBIO is a Neutral.

The overall stock score reflects significant financial challenges, including declining revenues and high leverage, which are major concerns. While technical indicators show some positive momentum, and the earnings call provided optimistic guidance, the negative valuation metrics and regulatory challenges weigh heavily on the stock’s outlook.

To see Spark’s full report on FBIO stock, click here.

More about Fortress Biotech

Fortress Biotech, Inc. operates in the biotechnology industry, focusing on developing and commercializing pharmaceutical and biotechnology products. The company is involved in various therapeutic areas through its subsidiaries, including Journey Medical Corporation, which contributes to its market focus.

Average Trading Volume: 729,313

Technical Sentiment Signal: Hold

Current Market Cap: $90.94M

For a thorough assessment of FBIO stock, go to TipRanks’ Stock Analysis page.